Source:http://linkedlifedata.com/resource/pubmed/id/18062963
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2008-2-25
|
pubmed:abstractText |
To examine the roles of endogenous K-ras 4A and K-ras 4B splice variants in tumorigenesis, murine lung carcinogenesis was induced by N-methyl-N-nitrosourea (MNU), which causes a K-ras mutation (G12D) that jointly affects both isoforms. Compared with age-matched K-ras(tmDelta4A/-) mice (where tumours can express mutationally activated K-ras 4B only), tumour number and size were significantly higher in K-ras(+/-) mice (where tumours can also express mutationally activated K-ras 4A), and significantly lower in K-ras(tmDelta4A/tmDelta4A) mice (where tumours can express both wild-type and activated K-ras 4B). MNU induced significantly more, and larger, tumours in wild-type than K-ras(tmDelta4A/tmDelta4A) mice which differ in that only tumours in wild-type mice can express wild-type and activated K-ras 4A. Lung tumours in all genotypes were predominantly papillary adenomas, and tumours from K-ras(+/-) and K-ras(tmDelta4A/-) mice exhibited phospho-Erk1/2 and phospho-Akt staining. Hence (1) mutationally activated K-ras 4B is sufficient to activate the Raf/MEK/ERK(MAPK) and PI3-K/Akt pathways, and initiate lung tumorigenesis, (2) when expressed with activated K-ras 4B, mutationally activated K-ras 4A further promotes lung tumour formation and growth (both in the presence and absence of its wild-type isoform) but does not affect either tumour pathology or progression, and (3) wild-type K-ras 4B, either directly or indirectly, reduces tumour number and size.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0014-4827
|
pubmed:author |
pubmed-author:ArendsMark JMJ,
pubmed-author:BerryRachel LRL,
pubmed-author:BrownsteinDavid GDG,
pubmed-author:DevenneyPaul SPS,
pubmed-author:HaganSuzanneS,
pubmed-author:HarrisonDavid JDJ,
pubmed-author:HooperMartin LML,
pubmed-author:KolchWalterW,
pubmed-author:LuoFeijunF,
pubmed-author:PatekCharles ECE,
pubmed-author:PlowmanSarah JSJ,
pubmed-author:RoseLorraineL,
pubmed-author:SansomOwen JOJ,
pubmed-author:WalkerMarionM,
pubmed-author:WallaceWilliam A HWA
|
pubmed:issnType |
Print
|
pubmed:day |
10
|
pubmed:volume |
314
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1105-14
|
pubmed:meshHeading |
pubmed-meshheading:18062963-Animals,
pubmed-meshheading:18062963-Disease Progression,
pubmed-meshheading:18062963-Lung Neoplasms,
pubmed-meshheading:18062963-Methylnitrosourea,
pubmed-meshheading:18062963-Mice,
pubmed-meshheading:18062963-Mice, Knockout,
pubmed-meshheading:18062963-Mutagenesis,
pubmed-meshheading:18062963-Mutant Proteins,
pubmed-meshheading:18062963-Protein Isoforms,
pubmed-meshheading:18062963-Signal Transduction,
pubmed-meshheading:18062963-Tumor Burden,
pubmed-meshheading:18062963-ras Proteins
|
pubmed:year |
2008
|
pubmed:articleTitle |
Mutationally activated K-ras 4A and 4B both mediate lung carcinogenesis.
|
pubmed:affiliation |
Sir Alastair Currie Cancer Research UK Laboratories, Molecular Medicine Centre, The University of Edinburgh, Western General Hospital, Edinburgh, UK.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|